TY - JOUR
AB - th Abstracts of the 10 Congress of ECCO - European Crohn’s and Colitis Organisation S57 Results: 119 patients (SU n=60) were included in the analysis. At Results: Median LI (IQR) was 2.3 (1.2-3.9) at first evaluation, 3.9 (1.6- the start of follow-up, 81.8% (60.0% AZA, 21.8% methotrexate) 9.8) 2-5 yr after diagnosis, and 8.3 (1-12.3) at 5-10 yr. LI increased vs. 66.0% (50.9% AZA, 11.3% methotrexate) of patients used an significantly (p< 0.0001) at 2-5 yr and 5-10 yr compared to its initial immunomodulator, and 20.0% vs. 15.1% received IFX in TD and value and from 2-5 yr to 5-10 yr. Last value of LI after 73 months (51- SU, respectively. The number of semesters in clinical remission did 96) was >2.0 in 138 patients (63%). These patients did not differ from not differ between TD and SU (67.3% vs. 68.0%; p=0.82). However, those without DD regarding demographic data and characteristics of patients in the TD group had fewer semesters with a flare (13.3% CD collected at diagnosis, however their earliest LI was significantly vs. 19.9%; p<0.01), and longer flare-free survival (median 9 vs. 5 increased. During follow-up 90 patients eventually required intestinal semesters; p=0.02). Mean time to first hospitalization 
TI - DOP057. Evolution of the Lémann Index (LI) during the course of Crohn’s disease (CD)
JF - Journal of Crohn's and Colitis
DO - 10.1093/ecco-jcc/jju027.085
DA - 2015-02-19
UR - https://www.deepdyve.com/lp/oxford-university-press/dop057-evolution-of-the-l-mann-index-li-during-the-course-of-crohn-s-l5uZGCsouy
SP - S57
EP - S57
VL - 9
IS - suppl_1
DP - DeepDyve
ER -